<div id="readability-page-1"><div> <div> , /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 20 at 9:30am ET Location: New York, NY Stifel 2026 Virtual Ophthalmology Forum Fireside Chat: Tuesday, May 26 at 9:30am ET Location: Virtual Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM. Contacts: Dana Cormack Corporate Communications [email protected] Investors: George E. MacDougall Investor Relations [email protected] SOURCE REGENXBIO Inc. <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9UEg2MjAzMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxNjA1UFJfTkVXU19VU1BSX19fX19QSDYyMDMy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9UEg2MjAzMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxNjA1UFJfTkVXU19VU1BSX19fX19QSDYyMDMy"/></div> </div></div>

RGNX

SBIO

LABU

IBBQ

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in upcoming investor conferences, including the RBC Capital Markets Global Healthcare Conference on May 20 and the Stifel Virtual Ophthalmology Forum on May 26. Live webcasts will be available on their website, with archived replays for 30 days post-event. REGENXBIO focuses on gene therapy for rare and retinal diseases.

prnewswire

Regenxbio

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

ROYAL BANK OF CANADA

Stifel Financial

Nippon Shinyaku Co., Ltd.

Abbvie

NOVARTIS AG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Novartis AG

16:05 ETREGENXBIO to Participate in Upcoming Investor Conferences